
Anthropic gave Claude access to biology codebases, and it successfully designed a brand-new drug candidates against 15 diseases
​
Anthropic just published a massive report proving Claude can autonomously do drug discovery.
They gave Claude a single overarching prompt with no pre-selected targets, scaffolds, or manual rules.
Then they stepped back and watched.
Claude independently researched 16 complex biological targets, chose epitopes, installed open-source protein design models, orchestrated multi-tool pipelines, optimized its own candidates, and delivered 30 ranked molecular designs per target.
All in a 24-to-48-hour window.
Zero human input into any design decision.
Independent contract research organizations synthesized every design exactly as Claude delivered it and measured its binding in a lab.
The results are terrifyingly good.
Claude successfully designed functional, high-affinity protein binders against 14 out of 15 testable targets.
Out of 1,320 total designs tested, 27% bound successfully.
For the top-ranked designs generated by the AI, the success rate hit an astonishing 49%.
On one notoriously difficult target (the RBX1 E3 ligase subunit) where a recent human-led open competition saw only 9 out of 245 designs bind, Claude crushed the benchmark.
28 of its 90 designs bound successfully.
Its tightest molecule achieved a binding affinity of 3.9 nM—shattering the 45 nM record set by the human competition winner.
Traditional drug discovery takes months or years of expensive, specialized lab work per target.
Claude did it over a weekend using entirely open-source tools.